Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment

Basit Öğe Kaydı
dc.contributor.authorGergerlioglu, H. Serdar
dc.contributor.authorSavas, Haluk A.
dc.contributor.authorBulbul, Feridun
dc.contributor.authorSelek, Salih
dc.contributor.authorUz, Efkan
dc.contributor.authorYumru, Mehmet
dc.date.accessioned2020-03-26T17:17:05Z
dc.date.available2020-03-26T17:17:05Z
dc.date.issued2007
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOxidant nitric oxide (NO) and antioxidant superoxide dismutase (SOD) have been implicated to play a role in the pathogenesis of bipolar disorders. This is the first prospective study aimed to evaluate NO levels and SOD activity in bipolar disorder (type I manic episode) (BD-ME). 29 inpatient subjects with BD-ME and 30 healthy controls were included. Serum NO levels and SOD activity have been studied at 1st (NO [1st] and SOD [1st] respectively) and 30th days (NO [30th] and SOD [30th] respectively) after treatment. The clinical outcome was measured by Bech-Rafaelson Mania Scale (BRMS). The mean NO [1st] (p <.001) and NO [30th] levels (p <.00 1) were higher than controls, but SOD [ I st] (p <.001) and SOD [30th] (p <.001) activities in BD-ME were lower than controls. SOD1 activity was higher than SOD [30th] (p <.001), while there was no significance in comparison between NO [1st] and NO [30th] (p <.05). SOD [30th] activity is negatively correlated with the number of previous manic attacks and NO [1st] was negatively correlated with sleep item score of BRMS at first day. Also there was a significant correlation between NO [1st] levels and with the existence of a delusion. NO and SOD appear to play a role in the pathophysiological events occurring in BD, especially in BD-ME. This study for the first time showed the possible role of NO on sleep and the generation of delusions in the pathophysiology of BD. In the light of literature, induced glutamate pathway might be responsible for delusions in BD. The results of this research need further investigation to understand the oxidative vs antioxidative process in BD. (c) 2007 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.pnpbp.2006.12.020en_US
dc.identifier.endpage702en_US
dc.identifier.issn0278-5846en_US
dc.identifier.issn1878-4216en_US
dc.identifier.issue3en_US
dc.identifier.pmid17303295en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage697en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.pnpbp.2006.12.020
dc.identifier.urihttps://hdl.handle.net/20.500.12395/21257
dc.identifier.volume31en_US
dc.identifier.wosWOS:000246166100016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDen_US
dc.relation.ispartofPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectantimanic treatmenten_US
dc.subjectantioxidanten_US
dc.subjectbipolar disorderen_US
dc.subjectdelusionen_US
dc.subjectnitric oxideen_US
dc.subjectoxidanten_US
dc.subjectsleepen_US
dc.subjectsuperoxide dismutaseen_US
dc.titleChanges in nitric oxide level and superoxide dismutase activity during antimanic treatmenten_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu